Liu, Jiye http://orcid.org/0000-0001-7970-7508
Xing, Lijie
Li, Jiang http://orcid.org/0000-0002-9791-2553
Wen, Kenneth
Liu, Ning
Liu, Yuntong
Wu, Gongwei http://orcid.org/0000-0002-2509-2381
Wang, Su http://orcid.org/0000-0002-9463-6530
Ogiya, Daisuke
Song, Tian-Yu http://orcid.org/0000-0001-9834-6795
Kurata, Keiji http://orcid.org/0000-0003-1060-9218
Penailillo, Johany
Morelli, Eugenio http://orcid.org/0000-0002-8850-0442
Wang, Tingjian
Hong, Xiaoning http://orcid.org/0000-0001-8375-6572
Gulla, Annamaria
Tai, Yu-Tzu
Munshi, Nikhil http://orcid.org/0000-0002-7344-9795
Richardson, Paul
Carrasco, Ruben
Hideshima, Teru
Anderson, Kenneth C. http://orcid.org/0000-0002-6418-0886
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA050947, R01-CA178264, P01-155258)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
the Riney Family Myeloma Initiative
National Natural Science Foundation of China (82200224)
Natural Science Foundation of Shandong Province (ZR2021MH072)
Article History
Received: 17 July 2023
Accepted: 29 January 2024
First Online: 14 February 2024
Competing interests
: K.C.A. serves on advisory boards to Pfizer, AstraZeneca, Janssen, Starton, Window, and Bristol Myers Squibb; and is a Founder of OncoPep, C4 Therapeutics, Dynamic Cell Therapies, and NextRNA. All the other authors declare no competing interests.